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bstract
The anti-cancer chemotherapeutic potential of 1,10-phenanthroline-5,6-dione (phendione), [Cu(phendione)3](ClO4)2·4H2O and
Ag(phendione)2]ClO4 were determined using four human cells lines, i.e. two neoplastic (A-498 and Hep-G2) and two non-neoplastic
CHANG and HK-2). All of the phendione derivatives induced a concentration-dependant decrease in the viability of the four cell
ines, with [Cu(phendione)3](ClO4)2·4H2O displaying greatest activity. In comparative studies, IC50 values obtained with the two
eoplastic cell lines showed a cytotoxic response which was between 3 and 35 times greater than that observed for the metal-based
nti-cancer agent, cisplatin. Furthermore, metal–phendione complexes, rather than simple solvated metal ions, were responsible
or the observed cytotoxicity. Despite the high level of potency associated with these compounds they did not display an apparent
yto-selective profile, as they reduced the viability of both neoplastic and non-neoplastic cells. However, selected mechanistic
tudies showed that phendione and its metal complexes inhibited DNA synthesis which did not appear to be mediated through
ntercalation. Ames testing highlighted that all three compounds and their phase I metabolites were non-mutagenic, unlike cisplatin.
aken together, these results suggest that phendione and its Cu(II) and Ag(I) complexes may be capable of acting as highly effective
nti-cancer therapies, which with careful administration could provide very potent and effective alternatives to cisplatin.
2006 Elsevier Ireland Ltd. All rights reserved.
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. IntroductionRecently there have been a number of reports
ighlighting the use of transition metal complexes as
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anti-cancer agents [1–3]. Probably the best known of
these is cisplatin [cis-diaminedichloroplatinum(II)]. It
has been widely used in the treatment of a variety of
cancers, especially testicular cancer, with a 70–90% cure
rate. When combined with other drugs, it has been used
successfully to treat brain, ovarian, bladder and breast
cancer [4]. The clinical success of cisplatin is limited
by its significant side effects, such as nausea, vomiting
and severe nephrotoxicity [4]. Additionally, acquired
ed.
116 C. Deegan et al. / Chemico-Biological IFig. 1. Structure of 1,10-phenanthroline (phen) and 1,10-phenanthro-
line-5,6-dione (phendione).
resistance has served to limit the widespread use of
cisplatin [5–7]. The employment of cisplatin and related
platinum complexes as anti-cancer agents has stimulated
the search for other active transition metal complexes
which are as effective, but with lesser side effects [5–7].
1,10-Phenanthroline (phen) (Fig. 1) and substituted
derivatives, both in the metal-free state and as lig-
ands co-ordinated to transition metals, disturb the
functioning of a wide variety of biological systems
[8]. Furthermore, when metal-free N,N′-chelating bases
are found to be bioactive it is usually assumed that
the sequestering of trace metals in situ is involved,
and that the resulting metal complexes are the active
species [9,10]. Previous work has shown that metal–phen
complexes [Cu(phen)2(mal)]·2H2O, [Mn(phen)2(mal)]·
2H2O and [Ag2(phen)3(mal)]·2H2O (malH2 = malonic
acid) inhibit growth of the fungal pathogen Candida
albicans by around 95% in a concentration range
1.25–5.0g/ml [11,12].
One of the most biologically active of the metal–phen
complexes is [Cu(phen)2]2+. This agent has been shown
to promote hydroxyl radical formation from molecular
oxygen by redox-cycling and could therefore be consid-
ered suitable for stimulating the production of reactive
oxygen species. Transition metal cations such as Cu(II)
and Fe(II) bind to negatively-charged DNA and have
been shown to play an important role in the local forma-
tion of •OH radicals [13,14]. One of the consequences of
high copper levels in the body is an increase in the rate of
radical formation leading to oxidative damage [15]. This
leads to a disruption of lipid bilayers due to oxidation and
cleavage of vulnerable unsaturated fatty acid residues
of phospholipids. Alterations in protein function are
also promoted through oxidation of thiol and possibly
amino groups. Gene expression may also be altered
due to oxidation of guanosine and adenosine residues
in nucleic acids, or altered transcription factor/growth
factor activities [15]. Tsang et al. [16] reported that
incubation of a human hepatic cell line (Hep-G2) withnteractions 164 (2006) 115–125
[Cu(phen)2]2+ resulted in internucleosomal DNA frag-
mentation, a hallmark of apoptosis. Zhou et al. [17]
also reported G1-specific apoptosis in a liver carcinoma
cell line (Bel-7402), caused by [Cu(phen)2]2+. Addi-
tionally, this complex was also shown to up-regulate
DNA-binding activity of p53, a pivotal molecule in the
regulation of cell progression, cell survival and apoptosis
[18].
1,10-Phenanthroline-5,6-dione (phendione) is a
chelate ligand containing an o-quinoid moiety which
is considered to have many interesting biological prop-
erties. Due to its redox activity, phendione both in its
metal-free state and in complexes with transition met-
als, such as ruthenium, cobalt, and osmium show strong
electrocatalytic activity in the oxidation of NADPH
[19–22]. Yokoyama et al. [22] have shown that ruthe-
nium complexes of phendione, particularly its qui-
nine moiety, can chemically modify proteins, such as
cytochrome c, resulting in increased reactivity suggest-
ing that these metal complexes may act as chemical
modifiers. More recently, Ghosh et al. [23] has studied
the ability of cobalt(III) complexes of phen and phen-
dione to interact with DNA using a variety of assays
including covalent binding assays, viscosity measure-
ments’ and competitive binding fluorescence measure-
ments. These researchers showed that the complexes
could intercalate within the base pairs of DNA, along
with cleaving plasmid DNA upon irradiation under
aerobic conditions. Furthermore, molecular modelling
was used to show that they could fit into the major
groove without disrupting the helical structure of B-
DNA. Based on these findings, these researchers suggest
that derivatives of phendione may display anti-cancer
activity, and studies are currently underway to prove this
theory.
The primary aim of the current study was to evaluate
the cancer chemotherapeutic potential of 1,10-phen-
anthroline-5,6-dione, [Cu(phendione)3](ClO4)2·4H2O
and [Ag(phendione)2]ClO4, using four human-derived
cancer cell lines. In order to ascertain the likely effect
of these agents on non-neoplastic cells, we decided to
include two cell lines, both derived from normal human
cells. These two non-neoplastic cells lines were chosen
as they provide the closest match with the neoplastic cell
lines currently commercially available. Furthermore, in
order to illustrate that the cytotoxic effect observed was
due to the complexes rather than the free metal ions,
the anti-tumour activities of the simple Cu(II) and Ag(I)
salts, Cu(ClO4)2 and AgClO4 were also determined. In
addition, the relative potency of these test agents was
determined by the inclusion of one of the best known and
most biologically active metal-based anti-cancer agents,
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isplatin. Aspects of the molecular mechanisms underly-
ng the anti-proliferative response were probed by inves-
igating the role of the complexes in mediating DNA
ynthesis and intercalation. This work presented here
epresents the first thorough assessment of the potential
pplication of phendione, [Cu(phendione)3](ClO4)2·
H2O, and [Ag(phendione)2]ClO4 as novel therapeutic
gents for the treatment of cancer.
. Materials and methods
.1. Test compounds
Cisplatin, Cu(ClO4)2·6H2O, AgClO4 and dimethyl
ulfoxide (DMSO) were purchased from Sigma–Aldrich
td. 1,10-Phenanthroline-5,6-dione (phendione) was
ade in accordance with the literature method [24].
Cu(phendione)3](ClO4)2·4H2O was prepared using
slight modification of the method used by Liu
t al. [25] in their synthesis of [Cu(phendione)3]
ClO4)2·2H2O·2MeCN [26]. [Ag(phendione)2]ClO4
as made by the method specified by McCann et al.
26]. All cell culture reagents and media were purchased
rom Euroclone, UK, unless otherwise stated. Structure
nd purity of phendione and its metal-based complexes
as confirmed by thin layer chromatography, infrared
nalysis, 1H and 13C NMR spectroscopy, along with
icroanalysis.
.2. Model cell lines
A-498 (human kidney adenocarcinoma), HK-2
human proximal tubular), CHANG (human hepatic)
nd Hep-G2 (human hepatocellular carcinoma) cells
ere purchased from the American Type Culture Col-
ection, Manassas, USA. A-498, CHANG and Hep-G2
ells were maintained in Eagle’s minimum essential
edium (EMEM) with Earle’s balanced salt solution
EBSS) containing 1.5 g/l sodium bicarbonate, 2 mM
-glutamine, 0.1 mM non-essential amino acids, 1 mM
odium pyruvate, 100 U/ml penicillin, 100g/ml strep-
omycin and 10% (v/v) foetal bovine serum (Sigma).
K-2 cells were maintained in Dulbecco’s modified
agle’s medium/Nutrient Hams F12 (50:50 v/v), supple-
ented with 2 mM l-glutamine, ITS (5g/ml bovine
nsulin, 5g/ml human transferrin and 5 ng/ml sele-
ium), 36 ng/ml hydrocortisone, 4 pg/ml 3,3′,5-triiodo-
-thyronine, and 10 ng/ml epidermal growth factor. All
ell lines were grown at 37 ◦C in a humidified atmo-
phere with 5% CO2, and were in the exponential
hase of growth at the time of inclusion in cytotoxicity
ssays.nteractions 164 (2006) 115–125 117
2.3. Assessment of cytotoxicity, using MTT assay
Phendione, [Cu(phendione)3](ClO4)2·4H2O, [Ag
(phendione)2]ClO4, cisplatin and the simple metal
salts Cu(ClO4)2·6H2O and AgClO4 were dissolved in
DMSO, diluted in culture media and used to treat
model cell lines for a period of 96 h. The maximum
percentage of DMSO present in all wells was 0.2%
(v/v). Cells were seeded in sterile 96-well flat-bottomed
plates (Sarstedt) at a density of 5 × 104 cells cm−3 and
grown in 5% CO2 at 37 ◦C. A miniaturised viability
assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) was carried out [27].
In metabolically active cells, MTT is reduced by the
mitochondrial enzyme succinate dehydrogenase to form
insoluble purple formazan crystals that are subsequently
solubilised, and the optical density (OD) measured spec-
trophotometrically. Therefore, drug-treated cells were
assayed by the addition of 20l of 5 mg/ml MTT in
0.1 M phosphate buffer saline (PBS), pH 7.4. Follow-
ing incubation for 4 h at 37 ◦C, the overlying media was
aspirated with a syringe and 100l of DMSO was added
to dissolve the formazan crystals. Plates were agitated at
high speed to ensure complete dissolution of crystals
and OD was measured at 550 nm using an Anthos HT-
II microtitreplate reader. Viability was expressed as a
percentage of solvent-treated control cells. Each drug
concentration had five replicates per assay and each
experiment was carried out on at least three separate
occasions. The IC50 value was calculated for each drug
and used as a parameter to compare the cytotoxicity of
each test compound. Consequently, the IC50 was defined
as the drug concentration (M) causing a 50% reduction
in cellular viability.
2.4. DNA synthesis studies
The effect of phendione, [Cu(phendione)3](ClO4)2·
4H2O, and [Ag(phendione)2]ClO4 on DNA synthesis
was determined using the 5-bromo-2-deoxyuridine
(BrdU) colourimetric incorporation assay [29]. 100l
of A-498 and Hep-G2 cells were seeded into 96-well
plates to a density of 5 × 104 cells/ml and allowed to
adhere overnight, after which test compound was incu-
bated for 96 h prior to the addition of BrdU (10M), and
incubated for a further 4 h at 37 ◦C. Following removal
of media, cells were permeabilised and fixed by the
addition of FixDenatTM solution (200l/well), and then
incubated at room temperature for 30 min, after which
reagent was removed. Incorporated BrdU was detected
by the addition of anti-BrdU-POD antibody conjugate
(100l/well) (Roche), followed by incubation at room
gical I118 C. Deegan et al. / Chemico-Biolo
temperature for 2 h. Plates were washed three times with
wash buffer (supplied by the manufacturer), followed by
the addition of TMB substrate solution (100l/well) and
incubation at room temperature for 30 min, while being
protected from light. The reaction was then stopped by
the addition of 1 M H2SO4 (25l/well). The OD of sam-
ples was measured on a Sunrise ELISA reader at 450 nm
(reference wavelength 690 nm). Results for drug-treated
cells were expressed as percentage BrdU incorporation
(DNA synthesis) of solvent-treated control cells. Each
drug concentration had five replicates per assay and each
experiment was carried out on at least three separate
occasions.
2.5. DNA binding studies
pGEM-3Z plasmid DNA was purified from
Escherichia coli [strain JM 109 as previously cultured
in LB broth (Oxoid), containing 50g/ml ampicillin]
using a Qiagen isolation kit (Qiagen Ltd.). DNA
purity and concentration was determined spectropho-
tometrically using A260/A280 spectrophotometric
measurements. DNA concentration was adjusted to
1g/ml using 10 mM Tris–HCl, pH 7.5, containing
1 mM EDTA. Drug binding assays were carried out
using phendione, metal–phendione complexes and
the two simple metal salts, according to the method
described by Lorcozio and Long [29]. Briefly, DNA was
incubated for 2 h at 37 ◦C. Doxorubicin was employed
as a positive control throughout. DNA was separated
on a 1% (w/v) agarose gel in TBE (80 mM Tris–HCl,
pH 8; 40 mM boric acid; 2 mM EDTA), and stained
with ethidium bromide (5g/ml in TBE). Bands were
visualised by irradiation at 300 nm and photographed
using a Pharmaciae 3D imaging system.
2.6. Plate incorporation mutagenicity assay
A Standard Ames test was carried out using
phendione, [Cu(phendione)3](ClO4)2·4H2O and [Ag
(phendione)2]ClO4 at concentrations close to their
respective IC50 values (0–10M) as determined by MTT
assay above. Salmonella typimurium tester strains TA98
and TA102 were used to detect possible mutation by
both frame-shift and base-pair substitution, respectively.
Additionally, the mutagenic potential of phase I metabo-
lites of each of the three test phendione agents was
determined by the inclusion of an S9 fraction isolated
from rat hepatocytes, where the animal had previously
been exposed to Aroclor 1254. The number of revertant
colonies was determined and related to drug concentra-
tion [30].nteractions 164 (2006) 115–125
2.7. Statistics
Statistical evaluation of the untreated control cells
along with drug- and solvent-treated cells was calculated
using one-way ANOVA (analysis of variance). A proba-
bility of 0.05 or less was deemed statistically significant.
The following notation was used throughout, *p < 0.05,
**p < 0.01, ***p < 0.001, differences to control.
3. Results
The primary objective of the current study was
to ascertain the anti-cancer potential of phendione
and two of its metal-based complexes, namely
[Cu(phendione)3](ClO4)2·4H2O and [Ag(phendione)2]
ClO4, using two pairs of cell lines, one of neoplastic
and the second of non-neoplastic origin. In addition, key
aspects of the mechanism of action of these agents were
also determined.
3.1. Assessment of cytotoxicity
All test agents were initially incubated with four
human-derived cell lines, two neoplastic (A-498 and
Hep-G2) and two non-neoplastic cell lines (CHANG
and HK-2) in order to determine their cytotoxic pro-
file. Cellular viability was determined using MTT with
an incubation period of 96 h. Data obtained for phen-
dione and its metal complexes, along with the simple
metal salts AgClO4 and Cu(ClO4)2·6H2O is presented
in Figs. 2–4 and these graphs were used to calculate the
IC50 values presented in Table 1.
Figs. 2 and 3 clearly demonstrate that all of the
test compounds, particularly phendione, [Cu(phen-
dione)3](ClO4)2·4H2O, and [Ag(phendione)2]ClO4 pro-
duced a concentration-dependant cytotoxic response in
all four cell lines. Furthermore, using the neoplastic-
derived cell lines, the IC50 values (Table 1) for
the two phendione–metal complexes, and particu-
larly [Cu(phendione)3](ClO4)2·4H2O, were statistically
lower than those obtained for metal-free phendione.
This finding suggests that coordinated metal ions play
a major role in mediating the potency of the com-
plex. Additionally, [Cu(phendione)3](ClO4)2·4H2O is
the most cytotoxic agent, and in all four cell lines. Fur-
thermore, based on the IC50 values presented in Table 1,
it would appear that phendione and its two complexes
are toxic to all four model cells lines, suggesting that
these compounds are incapable of selectively killing can-
cer cells, while leaving normal cells viable. This effect
was also observed for cisplatin with the two renal cell
lines. Furthermore, in comparative cytotoxicity assays,
C. Deegan et al. / Chemico-Biological Interactions 164 (2006) 115–125 119
Table 1
Cytotoxic potential of phendione, [Cu(phendione)3](ClO4)2·4H2O, [Ag(phendione)2]ClO4, simple Cu(II) and Ag(I) perchlorate salts, along with
cisplatin using human renal (HK-2 and A-498) and hepatic (CHANG and Hep-G2) cell lines following continuous incubation for 96 h and MTT
assay
Compound HK-2 (IC50
(M) ± S.E.M.)
A-498 (IC50
(M) ± S.E.M.)
CHANG (IC50
(M) ± S.E.M.)
Hep-G2 (IC50
(M) ± S.E.M.)
Phendione 0.7 ± 0.08 4.2 ± 0.36 0.4 ± 0.01 1.4 ± 1.34
[Cu(phendione)3](ClO4)2·4H2O 0.5 ± 0.14* 0.88 ± 0.06* 0.2 ± 0.02* 0.78 ± 0.09*
[Ag(phendione)2]ClO4 0.8 ± 0.06* 1.4 ± 0.47* 0.3 ± 0.11* 0.86 ± 0.87*
Cu(ClO4)2·6H2O 200 ± 10.5 973.3 ± 26.67 >1000 >1000
AgClO4 65 ± 2.0 44.4 ± 2.34 19 ± 1.8 7.6 ± 0.70
Cisplatin 18 ± 2.7 14.0 ± 1.00 45 ± 2.9 15.0 ± 2.65
A graph of viability (% of solvent-treated control cells) vs. drug concentration was used to calculate IC values (M). Results are representative
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* Statistically distinct from that of the parent ligand at p < 0.05.
C50 values for phendione and its complexes show cyto-
oxicities of between 3 and 35 times greater than that
bserved for cisplatin (Table 1). This finding is signif-
cant, as it suggests that phendione and its metal-based
omplexes may be an even more potent alternative to
isplatin.
.2. Investigation of DNA as a possible molecular
arget
In an attempt to elucidate the key events respon-
ible for the observed reduction in cellular viabil-
ty, the effects on DNA synthesis were determined
sing BrdU incorporation assays. These assays were
arried out following a 96 h drug treatment period.
esults obtained suggest that phendione and the
etal–phendione complexes cause a dose-dependant
ecrease in DNA synthesis (Fig. 5). Furthermore, phen-
ione and [Cu(phendione)3](ClO4)2·4H2O appeared to
e the most potent agents across both neoplastic-derived
odel cell lines, a trend which was consistent with the
ytotoxicity data obtained from MTT assays.
The planar nature of the phendione molecule might
mply the possible involvement of intercalation in medi-
ting the observed toxic response. Therefore, elec-
rophoretic mobility shift assays were carried out, where
NA was incubated with test agents over a range
f drug concentrations (1, 10 and 200M) and sub-
equently separated by electrophoresis. The results
btained (Fig. 6) clearly indicate that phendione and
Cu(phendione)3](ClO4)2·4H2O did not alter the migra-
ion of any of the three forms of plasmid DNA (i.e.
uper-coiled, linear, or open-circular), unlike the posi-
ive control doxorubicin (Fig. 6). Similar results were
btained for [Ag(phendione)2]ClO4 (data not shown).
hese findings suggest that phendione and its Cu(II) and50
Ag(I) complexes do not intercalate DNA and thus pre-
sumably function by an alternative mechanism.
3.3. Investigation of mutagenic potential
The results obtained above suggest that phendione,
and particularly [Cu(phendione)3](ClO4)2·4H2O and
[Ag(phendione)2]ClO4, are potent anti-cancer agents
which function by inhibiting DNA synthesis. How-
ever, their usefulness would be limited if they also
induced cellular mutations. Here, the Standard Ames
test was employed to establish the mutagenic poten-
tial of the three phendione compounds along with their
phase I metabolites. Additionally, the ability of the
test agents to induce mutations by both frame-shift
and base-pair substitution was determined by the inclu-
sion of two distinct tester strains, namely TA98 and
TA102. The results presented in Fig. 7 show that nei-
ther phendione, [Ag(phendione)2]ClO4, nor their phase I
metabolites cause mutation by either frame-shift or base-
pair substitution. Similar results were also obtained for
[Cu(phendione)3](ClO4)2·4H2O (data not shown).
Finally, results presented here confirm that phen-
dione, and particularly [Cu(phendione)3](ClO4)2·4H2O
and [Ag(phendione)2]ClO4, are potent cytotoxic agents,
capable of decreasing both cellular viability and DNA
synthesis, but without the involvement of either interca-
lation or mutation. Taken together, our data suggest that
these compounds, while they do not display an apparent
cyto-selective nature, may offer an alternative to cisplatin
in the treatment of human cancers.4. Discussion
Phen and its copper complexes have previously been
shown to exert a range of biological activities, such
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Fig. 2. Effects of phendione, [Cu(phendione)3](ClO4)2·4H2O and
[Ag(phendione)2]ClO4 on the viability of (A) Hep-G2 and (B)
CHANG cells. All compounds showed a concentration-dependant
Fig. 3. Effects of phendione, [Cu(phendione)3](ClO4)2·4H2O and
[Ag(phendione)2]ClO4 on the viability of (A) A-498 and (B) HK-2
cells. All compounds showed a concentration-dependant decrease indecrease in viability and in both cell lines, following 96 h incubation.
Results are expressed as percentage viability of solvent-treated control
cells. Bars indicate ±S.E.M., n = 3.
as anti-tumour [31–33], anti-Candida [32,34], anti-
mycobacterial [35] and anti-microbial effects [36]. Addi-
tionally, phendione has recently been shown to exert
anti-fungal activity [26]. In this study, we attempted to
identify the anti-cancer chemotherapeutic potential of
phendione and two of its metal–phendione complexes,
[Cu(phendione)3](ClO4)2·4H2O and [Ag(phendione)2]
ClO4, along with characterising key aspects of their in
vitro mode of action. However, given the scope of theviability and both cell lines, following 96 h incubation. Results are
expressed as percentage viability of solvent-treated control cells. Bars
indicate ±S.E.M., n = 3.
current paper, this does not represent a thorough investi-
gation of their mechanism of action. Additionally, in the
current study, we acknowledge that there is the possibil-
ity that each of the effects observed here may be due to
either the parent compound (i.e. phendione and two of
its metal–phendione complexes) its metabolites or both,
the latter being formed within the cells during the spec-
ified incubation periods. Additionally, in attempting to
evaluate the cyto-selective nature of these test agents we
attempted to select human model cell lines that provide
the best possible means of comparison. However, it is
C. Deegan et al. / Chemico-Biological Interactions 164 (2006) 115–125 121
Fig. 4. Effects of the simple metal perchlorate salts, Cu(ClO4)2·6H2O
and AgClO4, on the viability of (A) A-498 and HK-2 cells along with
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Fig. 5. Effects of phendione, [Cu(phendione)3](ClO4)2·4H2O and
[Ag(phendione)2]ClO4 on DNA synthesis using BrdU incorporationB) Hep-G2 and CHANG cells. All salts promoted a decrease in via-
ility following 96 h incubation. However, AgClO4 appeared to be the
ost potent, and in both cell lines Results are expressed as percentage
iability of solvent-treated control cells. Bars indicate ±S.E.M., n = 3.
orth noting that the neoplastic and non-neoplastic cells
re not identical, since, their media requirements and
rowth kinetics differ. Hence, there remains the possi-
ility that these factors may contribute to the apparent
on-selective nature of the test agents.
Cispatin is one of the best-known metal-based drugs
urrently in clinical use [4]. It has been shown to be
ighly effective against a variety of solid tumours. How-
ver, severe nephrotoxicity and resistance [5–7], which
t exhibits and driven the search for compounds but
ith similar or enhanced potency and with significantlyeduced side-effects. The mode of action of cisplatin has
een studied extensively. It has been shown that on enter-
ng the cell, Cl− dissociates to leave a reactive complex
hich can react with water, which in turn reacts withassays in (A) A-498 and (B) Hep-G2 cells, following continuous expo-
sure for 96 h. All compounds produced a dose-dependant decrease in
DNA synthesis. Bars indicate ±S.E.M., n = 3.
DNA, forming inter- and intra-strand DNA cross-links.
It is this reaction which leads to local denaturation of
the DNA chain. In addition, cisplatin has been shown to
cause mitochondrial damage, and it arrests, cell cycle in
G phase, inhibits ATPase activity, and alters the cellular
transport system, eventually leading to apoptosis, inflam-
mation, and necrosis (reviewed by Ali and Moundhri
[37]).
The central objective of the current paper is to deter-
mine the anti-cancer potential of phendione and two
of its metal-based complexes, namely [Cu(phendione)3]
(ClO4)2·4H2O and [Ag(phendione)2]ClO4, using two
pairs of cell lines (one pair of neoplastic origin and
the second non-neoplastic). It was felt that this method
would allow us to clearly identify whether these
agents were capable of selectively killing cancer cells,
while leaving non-cancerous cells viable. Although
this approach is relatively new in in vitro anti-cancer
122 C. Deegan et al. / Chemico-Biological Interactions 164 (2006) 115–125
Fig. 6. Electrophoretic mobility shift assays were used to determine
the effects of phendione and [Cu(phendione)3](ClO4)2·4H2O on the
migration of pGEM-3Z supercoiled plasmid DNA for 2 h at 37 ◦C,
analysed by agarose electrophoresis and stained with ethidium bro-
mide. Results indicate that neither compound inhibited migration of
super coiled (SC), linear (L) or open circular (OC) forms of plas-
mid DNA, suggesting they do not intercalate DNA. Lane 1, negative
control (pGEM-3Z DNA); lane 2, positive control (pGEM-3Z DNA
and doxorubicin, 10M); lanes 3–5, phendione (pGEM-3Z DNA and
Fig. 7. Standard Ames tests were used to determine the mutagenic
potential of all test compounds using Salmonella typimurium tester
strains, TA98 and TA102, both in the presence and absence of a S9
fraction isolated from rat hepatocytes, where the animal had previously
been exposed to Aroclor 1254. Results presented for (A) phendione and
(B) [Ag(phendione)2]ClO4 (0–10M/plate) indicate that neither of
these compounds are mutagenic as they do not cause a dose-dependantphendione at 1, 10 and 200M); lanes 6–8 (pGEM-3Z DNA and
[Cu(phendione)3](ClO4)2·4H2O at 1, 10 and 200M). Similar results
were obtained for [Ag(phendione)2]ClO4 (data not shown).
studies, we felt that it was appropriate, as it provided
a more detailed picture of the potential usefulness
and limitations associated with novel experimental
drugs. In addition, the two simple metal salts, namely
Cu(ClO4)2·6H2O and AgClO4, along with one of the
most commonly used anti-cancer agents cisplatin, were
included in our test protocol. It was intended that
this strategy would allow us to identify whether the
effects observed were due to the whole metal–phendione
complex rather than the simple aquated metal ions.
Additionally, it facilitates calculation of the relative
potency of the phendione derivatives to that of cis-
platin. Initial viability studies showed that, follow-
ing 96 h exposure to the test reagents, phendione
and the two metal–phendione complexes, particularly
[Cu(phendione)3](ClO4)2·4H2O, produced IC50 values
significantly lower than cisplatin. Also, these agents with
the exception of Cu(ClO4)2·6H2O, were toxic to all four
of the model cells lines. However, it is noteworthy that
this effect was also observed for cisplatin, when using
the two renal cell lines. Interestingly, IC50 values for
phendione and its complexes were lower in the CHANG
and Hep-G2 cell lines, than in A-498 and HK-2 cells,
suggesting that, in general, cells of hepatic origin may
be more sensitive than renal. Therefore, it may be possi-
ble that our test agents do display a degree of selectivity
for one cancer cell type over another. So, while cyto-increase in the number of revertant colonies. Similar results were
obtained for [Cu(phendione)3](ClO4)2·4H2O (data not shown). Bars
indicate ±S.E.M., n = 3.
selectivity is a highly desirable characteristic for all
anti-cancer agents, it is often difficult to achieve, even
with cisplatin, a drug currently in clinical use. Addition-
ally, it may be possible that agents that act as potent
anti-proliferative agents may display limited selectivity,
as they function on a key cellular event, central to the sur-
vival of all cells. Therefore, it is possible that phendione
and its metal complexes may have value in the clinical
setting in the longer term, as the dose and frequency of
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se could be tailored by the clinician in response to the
atient’s needs.
In this study, we have shown that phendione and its
etal complexes display a greater degree of cytotoxicity
han cisplatin. This result, although encouraging, was not
nexpected, as Zhang et al. [3] had previously published
ndings suggesting that a ternary copper–phen com-
lex [Cu(phen)(l-threonine)(H2O)]ClO4, when exposed
o human epithelial cell lines, displayed IC50 values in
he M range, and with greater cytotoxicity than that
bserved for cisplatin. Additionally, Igdaloff et al. [38]
ave shown that metal-free phendione and its isomer
,7-phenanthroline-5,6-dione could inhibit the growth
f the two mouse-derived lymphoma cell lines S49 and
110. The IC50 values recorded for phendione were
.04–0.5M, and were lower than that obtained for the
,7-isomer. These researchers concluded that phendione
as the most active and postulated that the cytotoxic-
ty observed for this ligand may be due to inhibition of
NA and RNA synthesis. However, this hypothesis was
ot confirmed experimentally.
In the present study, we have shown that metal-
ree phendione, [Cu(phendione)3](ClO4)2·4H2O, and
Ag(phendione)2]ClO4 exert a concentration-dependant
ytotoxic response (Figs. 2 and 3). In addition, the results
uggest that the addition of a metal to the phendione
igand amplified the cytotoxic potential. However, there
emained the possibility that the observed cytotoxic-
ty was due to the simple aquated Cu(II) and Ag(I)
ons rather than the metal ions chelated by the phen-
ione ligand. Therefore, in order to explore this the-
ry more fully it was decided to include the simple
alts Cu(ClO4)2·6H2O and AgClO4 in our test proto-
ols. The results presented in Fig. 4 clearly indicate
hat although AgClO4 was the most potent simple salt
tudied. However, its cytotoxicity was significantly less
han that observed for either phendione or the two
etal–phendione complexes. These findings are fur-
her supported by results obtained from a similar study
arried out by Hidalago and Dominguez [39]. These
esearchers showed that AgClO4 could kill human der-
al fibroblasts at concentrations of 4–82M. So, while
gClO4 processes cytotoxic properties, it would appear
hat it is less cytotoxic than phendione and the Cu(II) and
g(I) phendione complexes.
It is widely recognised that any chemotherapeutic
gent which can significantly reduce DNA synthesis is
ikely to be of particular value in controlling cancer cell
ivision. DNA has been shown to be a key cellular tar-
et in mediating the cytotoxicity of cisplatin. Gosh et al.
23] have shown that cobalt(III) complexes of phen and
hendione could intercalate with DNA, and yet retainnteractions 164 (2006) 115–125 123
its overall structure. However, their usefulness as anti-
cancer agents remains to be defined. In this study we have
attempted to determine whether interaction with DNA
plays a similarly important role in mediating the cytotox-
icity of phendione and its metal complexes, by probing
their effect on DNA synthesis and also their ability to
intercalate with it. Data presented here (Fig. 5) sug-
gest that phendione, [Cu(phendione)3](ClO4)2·4H2O
and [Ag(phendione)2]ClO4 are capable of inhibiting
DNA synthesis in both neoplastic-derived cell lines, and
in a concentration-dependant manner. Furthermore, the
phendione ligand appeared to be the most activity, dis-
playing the greatest inhibition. This suggests that the
phendione ligand itself is capable of playing a significant
role in mediating DNA synthesis. Additionally, the cur-
rent data did not explain the relationship between expo-
sure to phendione-based compounds, decreased DNA
synthesis and ultimately cell death. The possibility that
these complexes, like cisplatin, could intercalate DNA
and thus lead to decreased viability was explored using
gel mobility shift assays [40]. The model used here pro-
poses that intercalating ligands must possess a planar
aromatic ring structure capable of hydrophobic interac-
tions with DNA base pairs and that, on binding of the
ligand, the double helix should become extended and
locally uncoiled. Local unwinding of the double helix
by an intercalating species causes an increase in the
size of the DNA molecule. The super-coiled form of
plasmid DNA migrates further than either linear or open-
circular forms and can be detected by electrophoretic
migration assays [41]. DNA was exposed to phendione
and the metal–phendione complexes over a range of
concentrations both above and below their IC50 values
(Table 1). The results presented in Fig. 6 clearly indicate
that none of these agents retarded the electrophoretic
mobility of supercoiled pGEM-3Z DNA, suggesting that
they did not intercalate DNA, and implying that their
inhibitory effects operate through an alternative mech-
anism. A recent study carried out by Ghosh et al. [23]
showed that cobalt complexes of phen and phendione
were capable of binding covalently to the DNA double
helix retaining the overall structure of the helix. Addi-
tionally, they showed that these complexes could cleave
plasmid DNA upon irradiation under aerobic conditions.
These researchers suggest that these complexes many
have anti-cancer activity, but this remains to be con-
firmed experimentally.
Cross et al. [42] have shown that cisplatin was muta-
genic using the Ames test, suggesting that using cisplatin
could lead to an increased risk of secondary malignan-
cies. They conclude that normal cells in patients under-
going treatment with cisplatin were at an increased risk
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of genotoxicity and that this must be taken into con-
sideration when deciding on cancer treatment with this
agent. In the current study, it was decided to use the
standard Ames test to determine if there was a similar
genotoxic risk associated with phendione and its metal-
based complexes. Additional assays were carried out in
the presence of an S9 fraction derived from rat hepato-
cytes, thereby allowing the mutagenic potential of phase
I metabolites also to be determined. Results from these
assays revealed that none of compounds caused a sig-
nificant increase in the number of revertant colonies,
either by base pair substitution or by frame shift, sug-
gesting that they, and their phase I metabolites, were non-
mutagenic (Fig. 7). These findings clearly indicate that if
phendione and the metal–phendione complexes were to
be employed therapeutically, their potential usefulness is
not likely to be limited by mutagenicity, unlike cisplatin.
In conclusion, the above findings suggest that
phendione, [Ag(phendione)2]ClO4, and particularly
[Cu(phendione)3](ClO4)2·4H2O are each capable of
decreasing cancer cell viability through an inhibition of
DNA synthesis, but unlike cisplatin they do not cause an
increased risk of genotoxicity. However, the exact mech-
anisms underlying the cytotoxicity of these compounds
remain to be elucidated. Additional studies are currently
underway in our laboratory to investigate more fully the
mode of cell death induced as a result of drug exposure,
along with the biochemical processes by which this is
controlled. It is anticipated that the results from these
studies will allow identification of key molecular targets
by which the balance between cancer cell viability and
death can be tipped in favour of patient survival. In addi-
tion, it is intended that these studies will facilitate the
development of highly effective anti-cancer therapies,
which with careful management could be tailored by the
clinician in response to the patient’s needs.
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